BigHat Biosciences is an innovative player in the biotechnology and pharmaceuticals industry, founded in 2019. The company specializes in developing novel protein therapeutics through its cutting-edge AI-guided antibody design platform. With a small but dynamic team of 1 to 50 employees, BigHat is at the forefront of harnessing artificial intelligence to revolutionize the way antibodies are designed and optimized for therapeutic use. This unique approach not only accelerates the development process but also aims to enhance the efficacy and safety of treatments, positioning BigHat as a vital contributor to the future of medicine.